Department of Chemical, Pharmaceutical and Agricultural Sciences (DoCPAS), University of Ferrara, 44121 Ferrara, Italy.
Department of Translational Medicine, University of Ferrara, 44121 Ferrara, Italy.
Molecules. 2024 Aug 28;29(17):4085. doi: 10.3390/molecules29174085.
Cu is gaining recognition not only for its diagnostic capabilities in nuclear medical imaging but also for its therapeutic and theranostic potential. The simultaneous β- and Auger emissions of Cu can be utilized to induce a therapeutic effect on cancerous lesions. The finding of the exceptional biodistribution characteristics of the radionuclide Cu, when administered as basic copper ions, has highlighted its potential therapeutic application in cancer treatment. Preclinical and clinical research on the effectiveness of [Cu]CuCl as a theranostic radiopharmaceutical has commenced only in the past decade. Current clinical studies are increasingly demonstrating the high specificity and uptake of [Cu]Cu by malignant tissues during early cancer progression, indicating its potential for early cancer diagnosis across various organs. This short review aims to present the latest preclinical studies involving [Cu]CuCl, offering valuable insights for researchers planning new in vitro and in vivo studies to explore the theranostic potential of [Cu]Cu.
铜不仅因其在核医学成像中的诊断能力而受到关注，还因其治疗和治疗潜力而受到关注。铜的β和俄歇同时发射可以用于诱导对癌性病变的治疗效果。当以基本铜离子形式给予放射性核素铜时，发现其具有异常的生物分布特征，这突出了其在癌症治疗中的潜在治疗应用。作为治疗诊断放射性药物的[Cu]CuCl 的临床前和临床研究仅在过去十年中才开始。目前的临床研究越来越多地表明，在早期癌症进展过程中，恶性组织对[Cu]Cu 的高特异性和摄取，表明其在各种器官的早期癌症诊断方面具有潜力。这篇简短的综述旨在介绍最新的涉及[Cu]CuCl 的临床前研究，为计划进行新的体外和体内研究的研究人员提供有价值的见解，以探索[Cu]Cu 的治疗诊断潜力。
